Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.46 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.42 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.42 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28675410 | 1.00 | GPR119 (0.46) | GPR119SMARCA2SMARCA4PBRM1KCNH2 | |
| SCHEMBL23164303 | 0.86 | MGLL (0.38) | ALDH1A1MAPT | |
| SCHEMBL31729169 | 0.85 | PRKCQ (0.39) | GPR119KCNH2METPRKCQALDH1A1 | |
| SCHEMBL22712090 | 0.83 | ALDH1A1 (0.52) | GPR119KCNH2METALDH1A1LMNA | |
| SCHEMBL30323005 | 0.83 | ALDH1A1 (0.52) | GPR119KCNH2METALDH1A1LMNA | |
| SCHEMBL30006357 | 0.82 | SMARCA2 (0.48) | GPR119SMARCA2SMARCA4PBRM1KCNH2 | |
| SCHEMBL31727586 | 0.81 | GPR119 (0.47) | GPR119SMARCA2SMARCA4PBRM1MET | |
| SCHEMBL16197392 | 0.81 | GPR119 (0.56) | GPR119SMARCA2SMARCA4PBRM1KCNH2 | |
| SCHEMBL16197393 | 0.81 | GPR119 (0.56) | GPR119SMARCA2SMARCA4PBRM1KCNH2 | |
| SCHEMBL29969656 | 0.81 | PDE10A (0.41) | GPR119KCNH2METALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637467-B2 | Inhibitor of BTK and mutants thereof | NEWAVE PHARMACEUTICAL INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20220363689-A1 | INHIBITOR OF BTK AND MUTANTS THEREOF | NEWAVE PHARMACEUTICAL INC. | 2022-11-17 | — | — | US | disclosed |
| US-20220135569-A1 | INHIBITOR OF BTK AND MUTANTS THEREOF | NEWAVE PHARMACEUTICAL INC. | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363689-A1 | INHIBITOR OF BTK AND MUTANTS THEREOF | BTK, SYK, LYN | GPR119 2757/4885SMARCA2 2654/4885SMARCA4 2353/4885 |
| US-20220135569-A1 | INHIBITOR OF BTK AND MUTANTS THEREOF | BTK, SYK, LYN | GPR119 2987/4885SMARCA2 2875/4885SMARCA4 2465/4885 |
| US-12637467-B2 | Inhibitor of BTK and mutants thereof | BTK, CNKSR1, SYK | GPR119 3421/4885SMARCA2 3562/4885SMARCA4 4072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.